EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic effects of Clostridium butyricum and Akkermansia muciniphila -derived postbiotics ameliorate DSS-induced colitis and associated tumorigenesis through immunomodulation and microbiota regulation in mice

Dengxiong Hua, Qin Yang, Xuexue Zhou, Daoyan Wu, Yingqian Kang, Lei Tang, Boyan Li, Zhengrong Zhang, Xinxin Wang, Wei Hong iD, Zhenghong Chen iD, Guzhen Cui iD

mSystems · 2026

DOI: 10.1128/msystems.00689-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSystems, 2026. Verfasst von Dengxiong Hua und 11 weiteren Autor:innen. Beteiligte Einrichtung: Guizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, Guizhou Medical University, Guiyang, China. Hauptthemen laut MEDLINE: Clostridium butyricum, Probiotics, Gastrointestinal Microbiome, Colitis. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guizhou Health Commission Project, High-level Innovation Talent Project of Guizhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a major precursor to colorectal cancer (CRC). Our previous study demonstrated that combined administration of the probiotics Clostridium butyricum (CB) and Akkermansia muciniphila (AKK) significantly alleviated IBD and CRC symptoms in mice. Increasing evidence suggests that probiotic metabolites (postbiotics) offer significant advantages in disease prevention and treatment without the stability and safety concerns associated with live bacterial therapies. To further explore the therapeutic potential of CB- and AKK-fermented metabolites against IBD and CRC, we established a DSS-induced IBD model and DSS/AOM-induced CRC orthotopic models in mice and evaluated the effects of CB and AKK metabolites on alleviating IBD and CRC. The results revealed that the fermented metabolites of CB and AKK (designated as SupCB and SupAKK, respectively) exhibited significant synergistic effects. Mixed fermented metabolites (designated as SupCBAKK) outperformed individual metabolites, significantly alleviating IBD and CRC symptoms by modulating immune responses, repairing the mucosal barrier, and ameliorating gut dysbiosis. Notably, SupCBAKK synergized with the immune checkpoint inhibitor anti-PD-L1 (aPD-L1), enhancing tumor sensitivity to immunotherapy and amplifying antitumor immune responses. These findings underscore the potential of SupCBAKK as a novel postbiotic formulation for mitigating IBD and CRC progression and offer innovative strategies for developing CB- and AKK-based therapeutic interventions. IMPORTANCE This study highlights the therapeutic potential of SupCBAKK, a novel postbiotic formulation derived from the combined fermentation metabolites of CB and AKK, IBD, and colitis-associated colorectal cancer through the modulation of gut microbiota and immunometabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium butyricumProbioticsGastrointestinal MicrobiomeColitisColorectal NeoplasmsAnimalsMiceImmunomodulationDextran SulfateMice, Inbred C57BLCarcinogenesisAkkermansiaDisease Models, AnimalMale

Stichwörter der Autor:innen

Akkermansia muciniphilaClostridium butyricumcolorectal cancer (CRC)inflammatory bowel disease (IBD)postbiotics

Substanzen

Dextran Sulfate

Autor:innen und Institutionen

  • Guizhou Key Laboratory of Microbio and Infectious Disease Prevention & Control, Guizhou Medical University, Guiyang, China.
  • Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education & School/Hospital of Stomatology Guizhou Medical University, Guiyang, China.
  • Collaborative Innovation Center for Prevention and Control of Endemic and Ethnic Regional Diseases Co-constructed by the Province and Ministry, Guiyang, China.
  • Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.
  • Collaborative Innovation Center for Prevention and Control of Endemic and Ethnic Regional Diseases Co-constructed by the Province and Ministry of China, Guiyang, China.
  • School of Public Health/Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education &Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.

ORCID-Profile: Wei Hong, Zhenghong Chen, Guzhen Cui

Förderung

  • National Natural Science Foundation of China
  • Guizhou Health Commission Project
  • High-level Innovation Talent Project of Guizhou
  • Excellent Young Talent Program of Guizhou Medical University
  • Guizhou Provence Key Laboratory
  • Scientists Workstation Guizhou Provence
  • The Local Science Foundation of Guizhou Provence Guided by Central Committee of China

Zitieren

APA

Hua, D., Yang, Q., Zhou, X., Wu, D., Kang, Y., Tang, L., Li, B., Zhang, Z., Wang, X., Hong, W., Chen, Z., & Cui, G. (2026). Synergistic effects of Clostridium butyricum and Akkermansia muciniphila -derived postbiotics ameliorate DSS-induced colitis and associated tumorigenesis through immunomodulation and microbiota regulation in mice. mSystems. https://doi.org/10.1128/msystems.00689-25

Vancouver

Hua D, Yang Q, Zhou X, Wu D, Kang Y, Tang L, et al. Synergistic effects of Clostridium butyricum and Akkermansia muciniphila -derived postbiotics ameliorate DSS-induced colitis and associated tumorigenesis through immunomodulation and microbiota regulation in mice. mSystems. 2026. doi:10.1128/msystems.00689-25

BibTeX
@article{Hua2026,
  author = {Hua, Dengxiong and Yang, Qin and Zhou, Xuexue and Wu, Daoyan and Kang, Yingqian and Tang, Lei and Li, Boyan and Zhang, Zhengrong and Wang, Xinxin and Hong, Wei and Chen, Zhenghong and Cui, Guzhen},
  title = {Synergistic effects of Clostridium butyricum and Akkermansia muciniphila -derived postbiotics ameliorate DSS-induced colitis and associated tumorigenesis through immunomodulation and microbiota regulation in mice},
  journal = {mSystems},
  year = {2026},
  doi = {10.1128/msystems.00689-25}
}
Kostenlos starten →